Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing

Thomas Desautels, Adam Zemla, Edmond Lau, Magdalena Franco, Daniel Faissol
doi: https://doi.org/10.1101/2020.04.03.024885
Thomas Desautels
Lawrence Livermore National Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Zemla
Lawrence Livermore National Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edmond Lau
Lawrence Livermore National Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Franco
Lawrence Livermore National Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Faissol
Lawrence Livermore National Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dfaissol@llnl.gov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Summary

Rapidly responding to novel pathogens, such as SARS-CoV-2, represents an extremely challenging and complex endeavor. Numerous promising therapeutic and vaccine research efforts to mitigate the catastrophic effects of COVID-19 pandemic are underway, yet an efficacious countermeasure is still not available. To support these global research efforts, we have used a novel computational pipeline combining machine learning, bioinformatics, and supercomputing to predict antibody structures capable of targeting the SARS-CoV-2 receptor binding domain (RBD). In 22 days, using just the SARS-CoV-2 sequence and previously published neutralizing antibody structures for SARS-CoV-1, we generated 20 initial antibody sequences predicted to target the SARS-CoV-2 RBD. As a first step in this process, we predicted (and publicly released) structures of the SARS-CoV-2 spike protein using homology-based structural modeling. The predicted structures proved to be accurate within the targeted RBD region when compared to experimentally derived structures published weeks later. Next we used our in silico design platform to iteratively propose mutations to SARS-CoV-1 neutralizing antibodies (known not to bind SARS-Cov-2) to enable and optimize binding within the RBD of SARS-CoV-2. Starting from a calculated baseline free energy of −48.1 kcal/mol (± 8.3), our 20 selected first round antibody structures are predicted to have improved interaction with the SARS-CoV-2 RBD with free energies as low as −82.0 kcal/mole. The baseline SARS-CoV-1 antibody in complex with the SARS-CoV-1 RBD has a calculated interaction energy of −52.2 kcal/mole and neutralizes the virus by preventing it from binding and entering the human ACE2 receptor. These results suggest that our predicted antibody mutants may bind the SARS-CoV-2 RBD and potentially neutralize the virus. Additionally, our selected antibody mutants score well according to multiple antibody developability metrics. These antibody designs are being expressed and experimentally tested for binding to COVID-19 viral proteins, which will provide invaluable feedback to further improve the machine learning–driven designs. This technical report is a high-level description of that effort; the Supplementary Materials includes the homology-based structural models we developed and 178,856 in silico free energy calculations for 89,263 mutant antibodies derived from known SARS-CoV-1 neutralizing antibodies.

Footnotes

  • 1 This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under contract DE-AC52-07NA27344. Lawrence Livermore National Security, LLC.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 10, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing
Thomas Desautels, Adam Zemla, Edmond Lau, Magdalena Franco, Daniel Faissol
bioRxiv 2020.04.03.024885; doi: https://doi.org/10.1101/2020.04.03.024885
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing
Thomas Desautels, Adam Zemla, Edmond Lau, Magdalena Franco, Daniel Faissol
bioRxiv 2020.04.03.024885; doi: https://doi.org/10.1101/2020.04.03.024885

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Bioinformatics
Subject Areas
All Articles
  • Animal Behavior and Cognition (3704)
  • Biochemistry (7834)
  • Bioengineering (5708)
  • Bioinformatics (21364)
  • Biophysics (10614)
  • Cancer Biology (8218)
  • Cell Biology (11989)
  • Clinical Trials (138)
  • Developmental Biology (6792)
  • Ecology (10432)
  • Epidemiology (2065)
  • Evolutionary Biology (13919)
  • Genetics (9736)
  • Genomics (13118)
  • Immunology (8182)
  • Microbiology (20090)
  • Molecular Biology (7886)
  • Neuroscience (43205)
  • Paleontology (321)
  • Pathology (1285)
  • Pharmacology and Toxicology (2270)
  • Physiology (3367)
  • Plant Biology (7263)
  • Scientific Communication and Education (1317)
  • Synthetic Biology (2012)
  • Systems Biology (5552)
  • Zoology (1135)